BAXTER INTERNATIONAL INC
BAXNYSETrading Snapshot
- Day Range
- $23.08 β $23.78
- 52-Week Range
- $15.73 β $30.00
- Volume
- $2.70B
- Avg Volume
- $2.00B
- Shares Outstanding
- 517.0M
- Next Earnings
- Dec 4, 2026
Fundamentals Snapshot
- Annual Revenue
- $11.24B
- Last Q Revenue
- $2.96B
- P/E Ratio
- -11.5
- P/S Ratio
- 1.1x
- EPS (TTM)
- $-2.06
- Dividend Yield
- 0.17%
- Dilution (1yr)
- +0.8%
Why Investors Own BAX
- βHigh-growth profile β revenue up +6.6% YoY with expanding US Equity exposure.
- βHealthy economics β 70% gross margin and 28% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BAXTER INTERNATIONAL INC
BAXAbout BAXTER INTERNATIONAL INC
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Here's Why You Should Retain Baxter Stock in Your Portfolio for Now
BAX's portfolio reset and growth in connected care and advanced surgery support prospects, but margins, Novum IQ and China pricing remain risks.

Bank of America Corp DE Makes New Investment in Baxter International Inc. $BAX
Bank of America Corp DE acquired a new position in Baxter International Inc. (NYSE: BAX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor

Baxter International Inc. $BAX Shares Bought by NewEdge Advisors LLC
NewEdge Advisors LLC boosted its position in shares of Baxter International Inc. (NYSE: BAX) by 22.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Comm

TELA Bio (NASDAQ:TELA) versus Baxter International (NYSE:BAX) Head to Head Analysis
Baxter International (NYSE: BAX - Get Free Report) and TELA Bio (NASDAQ: TELA - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength

Baxter International Inc. (BAX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Baxter International Inc. (BAX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript